![Quiver Logo](/static/img/logo-icon.png)
![MYNZ logo](https://quiver-logos.s3.us-east-2.amazonaws.com/mynz.png)
Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MYNZ Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of MYNZ by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MYNZ's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to MYNZ
Recent picks made for MYNZ stock on CNBC
ETFs with the largest estimated holdings in MYNZ
Flights by private jets registered to MYNZ
![Quiver Logo](/static/img/logo-icon.png)